[DOI] [Google Scholar] 396.Ali D, Alarifi S, Alkahtani S, AlKahtane AA, Almalik A
For more information about Eccogene's GLP-1RA program and pipeline, visit www.eccogene.com About ECC5004 ECC5004 is a once daily, low dose, small molecule GLP-1RA which is currently in a US Phase I clinical trial in healthy participants and patients with type 2 diabetes (T2D)
Additionally, studies focusing on the individual benefits of each supplement have shown promise in areas like reducing inflammation and improving joint health
And it plays a role in buffering the mitochondrial acyl-CoA pool, helping maintain metabolic flexibility, the ability to switch between fat and carbohydrate as fuel sources depending on demand
We also love products that are made in the US and that come in more sustainable packaging